Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 3/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26421434 | 0.84 | OPRM1 (0.38) | OPRM1HTR2AHDAC1TACR1DPP9 | |
| SCHEMBL24944588 | 0.83 | OPRM1 (0.44) | OPRM1HTR2AHDAC1SIGMAR1OPRD1 | |
| SCHEMBL24944262 | 0.81 | OPRM1 (0.45) | OPRM1HTR2AHDAC1TACR1SIGMAR1 | |
| SCHEMBL24944237 | 0.81 | LMNA (0.43) | OPRM1HDAC1CYP1A2CYP2D6 | |
| SCHEMBL24944587 | 0.81 | OPRM1 (0.45) | OPRM1HTR2AHDAC1TACR1SIGMAR1 | |
| SCHEMBL26413364 | 0.80 | OPRM1 (0.56) | OPRM1OPRD1OPRK1 | |
| SCHEMBL26413446 | 0.80 | OPRM1 (0.41) | OPRM1HTR2ASIGMAR1OPRD1OPRK1 | |
| SCHEMBL23647372 | 0.79 | OPRM1 (0.47) | OPRM1HTR2AHDAC1TACR1DPP9 | |
| SCHEMBL26413649 | 0.79 | CYP1B1 (0.43) | OPRM1 | |
| SCHEMBL24944254 | 0.78 | OPRM1 (0.47) | OPRM1HTR2AHDAC1TACR1DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230131303-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230021453-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | HNRNPU, NSUN2, HNRNPR | OPRM1 775/4885HTR2A 3805/4885HDAC1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.